Krystal Biotech, Inc. reported $440M of revenue over the trailing twelve months, +23% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $440M (to Q2 2026). Net income: $241M, trailing twelve months to Q2 2026. Free cash flow: $258M, trailing twelve months to Q2 2026. Operating margin: 45%, trailing twelve months to Q2 2026.

KRYSKrystal Biotech, Inc.

Healthcare

$331.81+103% 1Y

$331.81

$161.1552 weeks$371.35

KRYS as reported

Krystal Biotech, Inc. reported $440M of revenue over the trailing twelve months, +23% on the year before. 9 reported series are charted on this page, each one as filed.

$440M

Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before

Net income: $241M
Net income · +65% year on year · trailing twelve months to Q2 2026
Free cash flow: $258M
Free cash flow · +39% year on year · trailing twelve months to Q2 2026
Operating margin: 45%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for KRYS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$440M	+23%	Q2 2026
Net income	$241M	+65%	Q2 2026
EPS	$7.98	+62%	Q2 2026
Operating margin	45%	n/a	Q2 2026
Net margin	56%	n/a	Q2 2026
ROE	17%	n/a	Q2 2026
ROA	16%	n/a	Q2 2026
Free cash flow	$258M	+39%	Q2 2026
P/E	41.6	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.